{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:42:31Z","timestamp":1787064151101,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.anai.2016.08.035","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T05:30:43Z","timestamp":1477287043000},"page":"514-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4+CD25+CD134+ lymphocytes"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6063-2403","authenticated-orcid":false,"given":"Jettanong","family":"Klaewsongkram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattarawat","family":"Thantiworasit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimpayao","family":"Sodsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supranee","family":"Buranapraditkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pungjai","family":"Mongkolpathumrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2016.08.035_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"Guilhot","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.anai.2016.08.035_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00003495-200363050-00005","article-title":"Imatinib mesylate: in the treatment of gastrointestinal stromal tumours","volume":"63","author":"Croom","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.anai.2016.08.035_bib3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2016.08.035_bib4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2016.08.035_bib5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mcna.2010.03.001","article-title":"The complex clinical picture of side effects to biologicals","volume":"94","author":"Hausmann","year":"2010","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.anai.2016.08.035_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.seminhematol.2010.06.003","article-title":"Current status of imatinib as frontline therapy for chronic myeloid leukemia","volume":"47","author":"Marin","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.anai.2016.08.035_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.seminhematol.2010.06.001","article-title":"Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?","volume":"47","author":"Fava","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.anai.2016.08.035_bib8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors: a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.anai.2016.08.035_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jjco\/hyp118","article-title":"Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor","volume":"40","author":"Bar-Sela","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.anai.2016.08.035_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.anai.2016.08.035_bib11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1081-1206(10)60016-6","article-title":"Desensitization to imatinib in patients with leukemia","volume":"97","author":"Nelson","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.08.035_bib12","first-page":"345","article-title":"Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature","volume":"25","author":"Park","year":"2004","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2016.08.035_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000073102","article-title":"Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign","volume":"207","author":"Banka","year":"2003","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.anai.2016.08.035_bib14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/1471-2407-10-438","article-title":"Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor","volume":"10","author":"Hwang","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.anai.2016.08.035_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0378-6323.16628","article-title":"Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose","volume":"71","author":"Pavithran","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.anai.2016.08.035_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000335637","article-title":"Desensitization for hypersensitivity reactions to medications","volume":"97","author":"del Carmen Sancho","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.anai.2016.08.035_bib17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/all.12161","article-title":"Desensitization in delayed drug hypersensitivity reactions: an EAACI position paper of the Drug Allergy Interest Group","volume":"68","author":"Scherer","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.08.035_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1871528111312010004","article-title":"Allopurinol\u00a0hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules","volume":"12","author":"Calogiuri","year":"2013","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.anai.2016.08.035_bib19","first-page":"6510","article-title":"Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses","volume":"161","author":"Gramaglia","year":"1998","journal-title":"J\u00a0Immunol Baltim Md 1950"},{"key":"10.1016\/j.anai.2016.08.035_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1189\/jlb.68.1.111","article-title":"Vascular endothelial cells provide T cells with costimulatory signals via the OX40\/gp34 system","volume":"68","author":"Kunitomi","year":"2000","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.anai.2016.08.035_bib21","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V95.7.2434","article-title":"Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation","volume":"95","author":"Tsukada","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.anai.2016.08.035_bib22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/90942","article-title":"Signaling through OX40 (CD134) breaks peripheral T-cell tolerance","volume":"7","author":"Bansal-Pakala","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.anai.2016.08.035_bib23","first-page":"2827","article-title":"High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)","volume":"183","author":"Zaunders","year":"2009","journal-title":"J\u00a0Immunol Baltim Md 1950"},{"key":"10.1016\/j.anai.2016.08.035_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jim.2011.10.004","article-title":"A\u00a0novel assay for detection of hepatitis C virus-specific effector CD4(+) T cells via co-expression of CD25 and CD134","volume":"375","author":"Keoshkerian","year":"2012","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.anai.2016.08.035_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ndt\/gfn461","article-title":"CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis","volume":"24","author":"Wilde","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.anai.2016.08.035_bib26","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2003-12-4266","article-title":"Imatinib mesylate inhibits T-cell proliferation in\u00a0vitro and delayed-type\u00a0hypersensitivity in\u00a0vivo","volume":"104","author":"Dietz","year":"2004","journal-title":"Blood"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616306263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616306263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:15:34Z","timestamp":1761052534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120616306263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1081120616306263"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2016.08.035","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4+CD25+CD134+ lymphocytes","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2016.08.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}